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Abstract High aldehyde dehydrogenase (ALDH) activity
can be used to identify tumor-initiating and metastasis-ini-
tiating cells in various human carcinomas, including pros-
tate cancer. To date, the functional importance of ALDH
enzymes in prostate carcinogenesis, progression and
metastasis has remained elusive. Previously we identiﬁed
strong expression of ALDH7A1 in human prostate cancer
cell lines, primary tumors and matched bone metastases. In
this study, we evaluated whether ALDH7A1 is required for
the acquisition of a metastatic stem/progenitor cell pheno-
type in human prostate cancer. Knockdown of ALDH7A1
expression resulted in a decrease of the a2
hi/av
hi/CD44
?
stem/progenitor cell subpopulation in the human prostate
cancer cell line PC-3M-Pro4. In addition, ALDH7A1
knockdown signiﬁcantly inhibited the clonogenic and
migratory ability of human prostate cancer cells in vitro.
Furthermore, a number of genes/factors involved in
migration, invasion and metastasis were affected including
transcription factors (snail, snail2, and twist) and osteo-
pontin, an ECM molecule involved in metastasis. Knock-
down of ALDH7A1 resulted in decreased intra-bone growth
and inhibited experimentally induced (bone) metastasis,
while intra-prostatic growth was not affected. In line with
these observations, evidence is presented that TGF-b, a key
player in cancer invasiveness and bone metastasis, strongly
induced ALDH activity while BMP7 (an antagonist of
TGF-b signaling) down-regulated ALDH activity. Our
ﬁndings show, for the ﬁrst time, that the ALDH7A1 enzyme
is functionally involved in the formation of bone metastases
and that the effect appeared dependent on the microenvi-
ronment, i.e., bone versus prostate.
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Abbreviations
ALDH Aldehyde dehydrogenase
BLI Wholebodybioluminescentreporterimaging
BMP Bone morphogenetic protein
CSC Cancer stem cell
EMT Epithelial-to-mesenchymal transition
GAPDH Glyceraldehyde-30-phosphate
dehydrogenase
OPN Osteopontin
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide
gel electrophoresis
shRNA Short hairpin RNA
TGF-b Transforming growth factor-b
Introduction
Prostate cancer metastatic disease, often occult at time of
diagnosis or surgery, is increasingly linked to mortality.
Secondary lesions are mostly found in the skeleton, indi-
cating bone as preferred site for the growth of disseminated
disease [1]. Understanding the mechanisms of prostate
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Acquisition of an invasive phenotype of cancer cells is a
requirement for bone metastasis; transformed epithelial
cells can switch to a motile, mesenchymal phenotype by
epithelial-to-mesenchymal transition (EMT) [2, 3]. Accu-
mulating evidence suggests that EMT may generate cancer
cells with properties of tissue stem cells [4–8]. Prostate
cancer cells with a stem/progenitor phenotype are believed
to be critically involved in prostate cancer initiation and
progression and recent evidence from our group also
indicated that this subpopulation of cancer cells is involved
in bone metastasis formation [4–8].
An increasing number of studies support the notion that
the primary tumor is maintained by a small number of
cells, the cancer stem cells (CSCs) or tumor-initiating cells
(TICs). It is generally believed that cellular heterogeneity
in primary prostate cancers also arises from this subpopu-
lation with stem/progenitor characteristics [4, 7, 9–11].
Because of the heterogeneous nature of solid cancers,
the reliability of cell surface markers as the sole way to
isolate TICs has remained controversial [4, 11–16]. A
complementary strategy for identifying TICs involves
measurement of aldehyde dehydrogenase (ALDH) activity.
ALDH is a detoxifying enzyme which has important
functions in the development of epithelial homeostasis, and
as a result, deregulation of this class of enzymes has been
implicated in multiple cancers [17]. ALDH activity is
involved in detoxiﬁcation, drug resistance, cell prolifera-
tion, differentiation, and response to oxidative stress [18–
21]. It is becoming increasingly clear that ALDH activity
can be used, either alone or in combination with cell sur-
face markers, to identify TICs [4, 22–26]. In a recent study,
we showed that human prostate cancer cells with high
ALDH activity are enriched for tumor- and metastasis-
initiating cells [4]. This ALDH
hi subpopulation showed
increased clonogenic and migratory ability in vitro and
enhanced tumorigenic and metastatic ability in vivo. At
present, it is not clear whether different ALDH isoforms
contribute to the high ALDH activity observed in highly
tumorigenic and metastatic prostate cancer cells. The
reagent ALDEFLUOR
TM
that is frequently used for viable
cell sorting based on ALDH activity has only been vali-
dated for ALDH1 and ALDH3 and not for the remaining
17 ALDH enzymes [17]. The prognostic signiﬁcance of
ALDH1 expression has been reported in a number of epi-
thelial tumors, but the role of other ALDH enzymes in
prostate cancer has not been addressed to date [22, 23, 26–
31].
Previously, we found high levels of ALDH7A1 in var-
ious prostate cancer cell lines and primary cultures. Strong
ALDH7A1 immunolocalization was also observed in pri-
mary prostate cancer tissue and matched bone metastases
[4]. The functional involvement of ALDH7A1 in prostate
cancer progression and metastasis has not been addressed.
In this paper we investigated the role of ALDH7A1 in
prostate cancer initiation, progression, and bone metastasis
formation by generating prostate cancer cells with stable
knockdown of ALDH7A1. Our ﬁndings indicate that
ALDH7A1 is involved in bone metastasis formation and
that the functional involvement of ALD7A1 is dependent
on the tumor microenvironment. Furthermore, the observed
differences in the size of prostate cancer stem/progenitor
subpopulations reﬂects the previously found opposite role
of TGF-b and BMP7 on experimentally induced metastasis
[32].
Results
Generation of prostate cancer cells with stable
ALDH7A1 knockdown
A potential strategy for the identiﬁcation and isolation of
cells with a stem cell-like phenotype in hematological and
a number of epithelial malignancies involves selection
based on ALDH enzyme activity [4, 23, 33] using the
ALDEFLUOR
 assay. We have previously shown that
various ALDH isoforms are expressed in human prostate
cancer, all of which can theoretically contribute to the
observed ALDEFLUOR activity [4]. One of the ALDH
enzymes, ALDH7A1, was strongly expressed in various
prostate cancer cell lines, primary cultures and in primary
prostate cancer tissue with matched bone metastases [4]. In
the present study, we investigated the effects of blocking
ALDH7A1 activity on prostate cancer growth and (bone)
metastasis by using lentiviral short hairpin RNA
interference.
Different shRNAi constructs from the Sigma MISSION
library were used to knockdown ALDH7A1 activity and
two constructs showed a strong down-regulation of
ALDH7A1 compared to the non-targeted control prostate
cancer cells (Fig. 1a cell clone #1 and #2). Based on the
high level of knockdown, we selected cell clone #1
(ALDH7A1-kd-Pro4luc) for further characterization in
vitro and functional analysis in vivo and compared all
results to the non-targeted control prostate cancer cells
(NT-Pro4luc). Cell viability was conﬁrmed by trypan blue
exclusion prior to each experiment, and no differences
among experimental groups were observed (data not
shown). Potential impact on other ALDH isoforms was
investigated by q-PCR analysis (Supplemental Figure S1).
The expression levels of the ALDH isoforms 3A2, 5A1,
9A1 and 18A1 were not signiﬁcantly affected by the
ALDH7 knock down, whereas the expression levels of
ALDH4A1 and 6A1 displayed a minor increase.
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cellular invasion and cancer stem/progenitor
characteristics
Selection of cells based on high ALDH activity can be used
toenrichforprostatecancercellswithastem/progenitorcell
phenotype, thus linking ALDH activity (ALDEFLUOR) to
stem/progenitorphenotypes[4,23].ALDH7A1knockdown
resulted in a 21% decrease in ALDH activity as measured
withtheALDEFLUORassay(100% ± 1vs.79% ± 13for,
respectively the NT-Pro4luc and ALDH7A1-kd-Pro4luc
cells). This link is further illustrated by the fact that stable
knockdown of ALDH7A1 led to signiﬁcantly decreased
clonogenicity compared to NT-Pro4luc control cells
(Fig. 1b). Furthermore, stable knockdown of ALDH7A1
resulted in a strongly impaired migratory response in a
Boyden Chamber assays (Fig. 1c). Blocking the activity of
ALDH7A1 in PC-3M-Pro4luc cells did not affect their
proliferation rates at various time points (Fig. 1d).
Upon stable ALDH7A1 knockdown, a concomitant
decrease in previously identiﬁed prostate cancer stem/
progenitor cell surface markers was observed (Fig. 2a).
Furthermore, ALDH7A1 knockdown in prostate cancer
cells, led to reduced expression of E-cadherin transcrip-
tional repressors (snail, snail2 and twist) and pro-metastatic
factors including N-cadherin, twist, and osteopontin (OPN)
(Fig. 2a) [34, 35]. In line with these observations, the
E-cadherin/vimentin ratio increased upon ALDH7A1
knockdown, indicating the generation of a more epithelial
and less invasive cell phenotype (Fig. 2b).
ALDH7A1 knockdown in prostate cancer cells
differentially affects orthotopic and intra-bone growth
in preclinical models
Our in vitro data showed that prostate cancer cells with a
strongly diminished ALDH7A1 activity are poorly clono-
genic and display a more sessile, epithelial phenotype
compared with control cells. Subsequently, we analyzed
and compared the tumorigenic and metastatic potential of
both cell lines in vivo.
When implanted orthotopically in the mouse prostate,
no signiﬁcant differences were observed in tumor growth
between both groups (Fig. 3a). Strikingly, we observed
marked differences in tumorigenicity and metastatic ability
in bone/bone marrow using our preclinical models of intra-
bone growth [4, 32, 36]. Tumor take and intra-bone tumor
growth were signiﬁcantly decreased in the ALDH7A1-
kd-Pro4luc group versus NT-Pro4luc control cells (Fig. 3b).
Inoculation of cancer cells into the left cardiac ventricle
of immunodeﬁcient mice is a widely used animal model of
bone metastasis [4, 32, 36]. Signiﬁcant differences in tumor
Fig. 1 Characterization of
ALDH7A1-kd-Pro4luc prostate
cancer cells. a Western blot
analysis of ALDH7A1
expression in NT-Pro4luc (ﬁrst
lane) and ALDH7A1-kd-
Pro4luc cells (cell clone #1 and
#2 derived from different
shRNAi constructs). b The
number of colonies per 96-well
plate in the single cell diluted
cultures after 2 weeks in the
ALDH7A1-kd-Pro4luc and NT-
Pro4luc cells. c Mean number of
migrated ALDH7A1-kd-
Pro4luc and NT-Pro4luc cells
per ﬁeld. d Absorbance
measured at 490 nm after 24,
48, and 72 h of incubation in
ALDH7A1-kd-Pro4luc (ﬁlled
circle) and control NT-Pro4luc
cells (open circle). Data are
representative for three
independent experiments
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123growth and metastasis formation were observed (Fig. 4). In
line with our intra-bone model, the ALDH7A1-kd-Pro4luc
cells failed to reproducibly generate bone metastases,
although limited growth was observed occasionally
(Fig. 4a). Furthermore, metastatic tumor burden was sig-
niﬁcantly lower in the ALDH7A1-kd-Pro4luc group com-
pared with the NT-Pro4luc control cells (Fig. 4b).
Moreover, the total number of (bone) metastases was sig-
niﬁcantly decreased in the mice injected with the
ALDH7A1 knockdown cells (Fig. 4c, d).
Regulation of the size of PC-3M-Pro4luc stem/
progenitor subpopulation
The TGF-b superfamily (including TGF-bs and BMPs)
plays a key role in EMT (tumor invasiveness), generation
of cancer stem cells, and bone metastasis. Our group
described previously that TGF-b and BMP7 have opposite
roles in oncologic EMT, where BMP7 can counteract TGF-
b induced EMT and inhibit bone metastasis [7, 8, 32].
Incubation with different concentrations of TGF-b for
72 h signiﬁcantly and dose-dependently increased the size
of the ALDH
hi subpopulation of prostate cancer stem/
progenitor cells, whereas incubation with different con-
centrations of BMP7 signiﬁcantly and dose-dependently
decreased the size of this subpopulation (Fig. 5a). Incu-
bation with BMP2, BMP4, and BMP7 decreased the size of
the ALDH
hi subpopulation signiﬁcantly (-56, -62, and
-67%, respectively), while the close homolog of BMP7,
BMP6, only marginally affected this subpopulation with
-25% (Fig. 5b).
Subsequently, we analyzed whether BMPs and TGF-b
affected the mRNA expression level of ALDH7A1 in
PC-3M-Pro4luc prostate cancer cells. In line with the data
shown in Fig. 5a and b we found that incubation with TGF-
b for 72 h signiﬁcantly increased the ALDH7A1 mRNA
expression level by 2.5 fold (Fig. 5c). In addition to TGF-
b, ALDH7A1 expression was inhibited upon incubation for
72 h with BMP2, 4, 6, and BMP7 (2.3 fold; 3.5 fold; 1.3
fold; and 5.0 fold inhibition, respectively). These q-PCR
data were conﬁrmed by Western blot analysis (2.5 fold
increase upon TGF-stimulation; Fig. 5d.).
Discussion
Once prostate cancer has spread to the skeleton, treatment
options are mainly focused on palliation and the prevention
of fractures. Due to the observed heterogeneity in primary
tumors and metastases, it has been a major challenge to
distinguish and select prostate cancer cells with tumor- and
metastasis-initiating ability. The functional identiﬁcation of
metastasis-initiating cells is a prerequisite for properly
targeted therapy of metastatic disease in advanced prostate
cancer.
It is becoming increasingly clear that ALDH activity
(ALDEFLUOR
TM
) can be used, either alone or in combi-
nation with other cell surface markers, to identify tumor-
initiating cells (TICs) in multiple carcinomas [22–26]. In
addition, we have shown recently that high ALDH activity
could be used to select for prostate cancer cells with
increased metastatic ability [4]. This was conﬁrmed by Yu
et al. [37] using subcutaneous implantations of prostate
cancer cells. Moreover, we found differential expression of
various ALDH isoforms in human prostate cancer, with
high expression of ALDH7A1 in several cell lines, primary
cultures, and primary prostate tissue with matched bone
metastases. This suggests that, besides the ALDH1 enzyme
which has been reported to be important in a number of
epithelial tumors [22, 23, 26, 27, 30, 31], other ALDH
isoforms may contribute to the overall ALDH activity and
Fig. 2 Differential expression of stem/progenitor markers and inva-
siveness-associated genes upon ALDH7A1 expression knockdown.
a q-PCR analysis of stem/progenitor cell markers and EMT-associ-
ated genes (av, a2, CD44, osteopontin, N-cadherin, snail, snail2, and
twist). Relative expression levels in ALDH7A1-kd-Pro4luc cells were
shown as compared to the NT-Pro4luc control cells. All values were
normalized for GAPDH and presented as mean ± sem. b Relative E-
cadherin/vimentin ratios of ALDH7A1-kd-Pro4luc and NT-Pro4luc
control cells as measured by q-PCR analysis. Data are representative
for two independent experiments
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123may be indicative of tumor-initiating and metastasis-initi-
ating cells.
Here we describe, for the ﬁrst time, the functional
involvement of ALDH7A1 in prostate cancer metastasis.
The size of this ALDH
hi subpopulation, encompassing the
cancer cells with tumor-and metastasis-initiating ability,
can be regulated by the TGF-b superfamily (TGF-b and
BMPs). We used the highly invasive (mesenchymal),
osteotropic prostate cancer cell line PC-3M-Pro4luc for
functional knockdown studies of ALDH7A1. Knockdown
of ALDH7A1 expression resulted in a decrease of the
prostate cancer stem/progenitor subpopulation, identiﬁed
by integrin a2, integrin av and CD44 [38–41]. In line with
the altered expression of these stem/progenitor markers in
the ALDH7A1-kd-Pro4luc cells, the clonogenic and
migratory ability of the cells was also signiﬁcantly
decreased in vitro. Furthermore, a number of genes/factors
involved in migration, invasion (EMT) and metastasis were
affected. It is important to note that knockdown of
ALDH7A1 in PC-3M-Pro4luc cells signiﬁcantly dimin-
ished bone metastasis and tumor growth in the bone mar-
row, while intra-prostatic cancer growth was not affected.
Our data suggest that ALDH7A1 is involved in many
important processes in prostate cancer and support the
notion that ALDH enzyme activity can be used to isolate
prostate cancer stem/progenitor cells, although it remains to
be established whether this isoform also plays a causal role
in other human and mouse prostate cancer cell lines. Both
EMT associated genes and stem/progenitor characteristics
were negatively affected upon ALDH7A1 knockdown. The
data presented in this article further substantiate the previ-
ously described association between EMT and cancer stem
cells [4–8]. For instance, snail and twist expression were
decreased in the ALDH7A1-kd-Pro4luc cells as compared
to the NT-Pro4luc control cells. The pro-metastatic tran-
scription factor and E-cadherin repressor twist was recently
associated with EMT and the promotion of the tumor-ini-
tiating capability in carcinomas [35]. Twist expression was
found to be linked to the generation of stem cell properties
of cancer cells. The data presented in this article further
extend and support this notion for prostate cancer, since
ALDH7A1 knockdown decreased twist expression, leading
to signiﬁcant reductions in clonogenic properties and
expression of prostate cancer stem cell markers.
Fig. 3 ALDH7A1 knockdown in prostate cancer cells differentially
affects orthotopic and intra-bone growth in preclinical models. a The
left panel demonstrates representative images of one mouse 14, 21,
and 28 days after orthotopic injection in the prostate with either
100,000 ALDH7A1-kd-Pro4luc or NT-Pro4 prostate cancer cells. The
right panel reveals total tumor burden for the mice injected with
the ALDH7A1-kd-Pro4luc knockdown population (closed circles)o r
the NT-Pro4luc control population (open circles)( n = 8/group).
b Representative images of mice intra-osseously inoculated with
either ALDH7A1-kd-Pro4luc or NT-Pro4luc cells (100,000) at
different days after inoculation. Total tumor burden of the mice
injected with ALDH7A1-kd-Pro4luc (closed circles) or NT-Pro4luc
cells (open circles) subpopulation (n = 8/group *P\0.05)
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EMT plays a critical role in the formation of bone metas-
tases and a stem/progenitor cell phenotype [7, 42–44]. In
cancer, EMT is fundamental for epithelial cells to become
more invasive. We show here that ALDH7A1 is necessary
for prostate cancer cells to acquire a metastatic phenotype
and form bone metastases, but is not pivotal for growth at
the orthotopic site. It appears that the bone microenviron-
ment plays an important role and provides crucial factors
for the tumor cells to grow. These data, therefore, provide
further evidence for the role of the stroma in the regulation
of tumor invasiveness and metastasis as was shown pre-
viously for BMP7 [36].
Osteoclasts resorb bone, thereby releasing growth fac-
tors like TGF-b that may promote tumor cell proliferation,
metastasis and survival, thus perpetuating a vicious cycle
of tumor expansion and bone resorption [36, 45]. Strik-
ingly, TGF-b increased the ALDH
hi population as well as
ALDH7A1 expression. One of the BMPs, BMP7, coun-
teracts the pro-tumorigenic effects of TGF-b [32], and
decreased the ALDH
hi population and expression of
ALDH7A1 in this study. This is in line with the notion that
BMP7 induces differentiation towards a more epithelial,
sessile tumor phenotype [32, 46–49]. In addition to TGF-b,
OPN is prominently expressed at the sites of bone
remodeling. Strikingly, TGF-b can induce OPN expression
in both bone and tumor cells [50, 51]. Binding of OPN to
the tumor cell membrane receptor CD44 can enhance
tumor cell motility, migration and invasion in a paracrine
and autocrine manner [52–55]. Knockdown of ALDH7A1
resulted in decreased OPN and CD44 expression in prostate
cancer cells, which could explain, at least in part, a slow-
down in intra-bone tumor growth and inhibition of (bone)
metastasis formation.
In conclusion, we show that the ALDH7A1 enzyme may
play a role in the formation of distant bone metastases.
Downregulation of ALDH7A1 does not impair tumor
growth at orthotopic sites but affects bone colonization and
intra-osseous growth. This observed effect of ALDH7A1
expression suggests a pivotal role for the microenviron-
ment and may be dependent on the presence of factors such
as TGF-b and OPN. Our studies show that stem/progenitor
phenotype in human prostate cancer cells can be differen-
tially affected by the ALDH7A1 enzyme and bone-active
Fig. 4 ALDH7A1 knockdown prostate cancer cells show decreased
metastatic growth in vivo. a Representative images of mice inocu-
lated intra-cardiac with either 100,000 ALDH7A1-kd-Pro4luc knock-
down or NT-Pro4luc control cells at day 21, 28, and 35 after
inoculation (n = 10/group). b Total tumor burden of ALDH7A1-kd-
Pro4luc cells (closed circles) compared with NT-Pro4luc cells (open
circles). c Total number of metastases per mouse in the mice injected
with either ALDH7A1-kd-Pro4luc cells (closed circles) or NT-
Pro4luc control cells (open circles). d Total number of bone
metastases per mouse in the mice injected with either ALDH7A1-
kd-Pro4luc (closed circles) NT-Pro4luc control (open circles) cells
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123growth factors like TGF-b and certain BMPs. Modulating
and targeting this stem/progenitor subpopulation might be
pivotal for the development of therapies for long-term
disease-free survival.
Methods
Cell lines and culture conditions
The human prostate cancer cell line stably expressing
ﬁreﬂy luciferase PC-3M-Pro4lucA6 (Pro4luc) was main-
tained in DMEM (GibcoBRL) containing 4.5 g glucose/l
supplemented with 10% FCII, 100 units/ml penicillin,
50 lg/ml streptomycin, and 800 lg/ml geneticin/G418
(Invitrogen) [36]. Puromycin in a concentration of 1 lg/ml
was added for Pro4lucA6 with stable shRNAi knockdown.
HEK293T cells were maintained in DMEM containing
10% FCS. All cell lines were grown in a humidiﬁed
incubator at 37C and 5% CO2.
Suppressing ALDH7A1 expression
with a shRNA-lentiviral vector
Short hairpin RNAi constructs (ALDH7A1 clone# TRCN
0000028463, TRCN0000028408 and TRCN0000028447)
were derived from Sigma’s MISSION library. HEK293T
cells were transfected with the short hairpin constructs
together with the packaging plasmids REV, GAG and VSV
in a 1:1:1:1 ratio using Fugene HD (Roche) as transfection
reagent. The supernatant of the culture medium containing
the lentiviral vector was collected 48 h after transfection.
Pro4lucA6 cells were mixed with 1 ml of shRNA-len-
tiviral vector and 8 lg Polybrene (Sigma) was added. The
Fig. 5 Regulation of the PC-3M-Pro4luc subpopulation with high
ALDH activity. a Human prostate cancer cells (PC-3M-Pro4luc) were
assayed with the ALDEFLUOR
 kit after stimulation for 3 days with
different concentrations of either BMP7 (50, 100, and 500 ng/ml) or
TGF-b (1, 5, and 10 ng/ml). b PC-3M-Pro4luc were assayed with the
ALDEFLUOR
 kit after stimulation for 3 days with either BMPs
(100 ng/ml BMP2, 4, 6, and 500 ng/ml BMP7) or 10 ng/ml TGF-b.
c mRNA expression levels of ALDH7A1 in PC-3M-Pro4luc cells
after stimulation for 3 days with either BMPs (BMP2, 4, 6, and 7) or
TGF-b as detected by qPCR. Data are representative for two
independent experiments. d Western blot analysis of ALDH7A1
protein expression after stimulation of PC-3M-Pro4luc cells with
TGF-b for 72 h. Intensities were normalized for b-actin
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123mixture was incubated for 1–2 h at room temperature.
Scrambled shRNA (clone# TRC1/1.5) was used as control
which lack homology with any mammalian mRNA
sequence. Cells stably expressing the shRNA were selected
using puromycin (1 lg/ml, Sigma).
The ALDH7A1 knockdown cell line will further be
referred to as ALDH7A1-kd-Pro4luc cells and the non-
targeting control cell line as NT-Pro4luc cells.
Western blot analysis
Cells were washed with PBS and lysed in SDS-sample
buffer (Laemmli buffer, Biorad). Proteins were separated
on SDS-PAGE and subjected to Western blotting using
standard techniques. Antibodies recognizing ALDH7A1
(1:5,000) was from Abcam and anti-b-actin (1:30,000) was
from Sigma-Aldrich. Proteins were detected by using a
chemiluminescence detection system from Roche.
FACS analysis
Expression of stem/progenitor- and EMT markers was
measured by FACS analysis using the Calibur2 ﬂow
cytometer (BD Biosciences) and FCS express software (De
Novo software USA). The cells (1 9 10
5 cells) were
incubated for 45 min at 4C in a solution of 90 ll FACS
wash buffer containing PBS ? 1% FCS ? 0.1% natriu-
mazide NaN3 and 10 ll antibody (av-PE, a2-FITC, CD44-
APC, CD44v6-APC, Miltenyi). To determine E-cadherin/
vimentin ratios, cells were harvested and labeled with
E-cadherin-FITC (BD Biosciences 1:10) in FACS buffer
for 30 min at 4C in the dark. Then cells were washed with
1 ml FACS buffer and ﬁxed with freshly prepared 2%
formaldehyde for 15 min. Cells were washed with ice cold
PBS and subsequently incubated for 30 min at 4C in the
dark with vimentin rabbit polyclonal antibody (Abcam
1:200 in FACS buffer). Cells were washed twice with 1 ml
of FACS buffer and incubated for 30 min at 4C with goat-
anti rabbit IgG-APC antibody (Invitrogen). After the last
incubation step, the cells were washed and centrifuged for
5 min followed by adding 250 ll FACS wash buffer.
ALDH activity was measured as described earlier [4].
RNA isolation and real-time qPCR
RNA was extracted using Trizol (Invitrogen) according to
manufacturer’s instructions. Real-time qPCR was run and
analyzed with a Biorad IQ5 cycler (Biorad). For primer
sequences see Supplemental Table 1. Gene expression was
measured relative to GAPDH expression using the fol-
lowing formula: Relative transcript abundance (RTA) =
10,000/2
(Ctgene-CtGAPDH).
Soft agar colony assay
Cell suspensions of both cell lines were generated (as
described previously [4]) and overlayed onto a 60 mm dish
containing a solidiﬁed bottom layer of 0.6% Noble agarose
(Beckton Dickenson) in medium. One ml of medium was
placed on top of the solidiﬁed cell layer. Plates were
incubated for 1–3 weeks until colonies were visible. The
colonies on the soft agar plates were counted by using light
microscopy (Zeiss Axiovert 200M). Three individual and
representative ﬁelds of each well were counted. The mean
number of colonies/ﬁeld was calculated.
Colony forming assay
Cells were seeded into a 96-wells plate containing an
average of one cell per well. Plates were monitored twice a
week and maintained in DMEM/10% FCII medium. After
1–3 weeks colonies were clearly visible and the mean
number of positive wells/plate was counted by microscopy
(Zeiss Axiovert 200M).
Migration assay
Tumor cell migration was performed in transwell migration
chambers (Costar) as described previously [4]. Three ran-
dom ﬁelds were counted for each well, and mean numbers
of migrated cells/ﬁeld were calculated.
Proliferation assay
Cells were seeded at a density of 2,500/cm
2 and allowed to
grow for, respectively, 24, 48, and 72 h. After the cell
incubation, 20 ll MTS was added to the medium and
mitochondrial activity was measured at 490 nm after 2 h
incubation at 37C (CellTiter96 Aqueous non-radioactive
cell proliferation assay (Promega)).
In vivo animal experiments
Mouse strains: Male nude (Balb/c nu/nu) mice were
housed in individual ventilated cages under sterile condi-
tion according to the local guidelines for the care and use
of laboratory animals (DEC07026 and 09052). Mice were
anaesthetized before surgical and analytical procedures
were performed.
Intra-osseous inoculation of Pro4luc cells: A single cell
suspension of 1 9 10
5 ALDH7A1-kd-Pro4luc cells or
NT-Pro4luc cells/10 ll PBS was injected into the right ti-
biae as described previously [4, 36, 56]. The progression of
cancer cell growth was monitored weekly by BLI (whole
body bioluminescent reporter imaging) as described below.
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prostate: A single cell suspension of 1 9 10
5 ALDH7A1-
kd-Pro4luc cells or NT-Pro4luc cells/10 ll PBS was
combined with 10 ll growth factor reduced matrigel (BD
Biosciences) and surgically inoculated into the prostate of
anaesthetized 6-week-old male nude mice [4, 48]. The
progression of cancer cell growth was monitored weekly by
BLI.
Intracardiac inoculation Pro4luc cells to induce sys-
temic metastases: A single cell suspension of 1 9 10
5
ALDH7A1-kd-Pro4luc cells or NT-Pro4luc cells per
100 ll PBS was injected into the left cardiac ventricle of
anaesthetized 5-week-old male nude mice and cancer cell
growth was monitored weekly by BLI [4, 36].
Whole body bioluminescent reporter imaging (BLI) and
quantiﬁcation of the bioluminescent signal:
For all in vivo experiments, the progression of cancer
cell growth was monitored weekly by bioluminescent
imaging using the IVIS100 Imaging System (Caliper Life
Science) as described earlier [36].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
4.0 software
 (San Diego, CA) using either t-test (for
comparison between two groups) or ANOVA (for com-
parison between more than two groups). Unless otherwise
stated, data is presented as the mean ± SEM. P values
of B0.05 were regarded as being statistically signiﬁcant
(*P\0.05, **P\0.01, ***P\0.001).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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